AZN: Q1 2019 Results
AstraZeneca PLC 26 April 2019 07:00 BST Q1 2019 Results Another strong top-line performance, with operating leverage supporting compelling growth in earnings Results in the first quarter were supported by Product Sales growth of 10% (14% at CER1) to $5,465m, a reflection of the sustained performance of new medicines2 (+77%, +83% at CER). Global Oncology sales increased by 54% (59% at CER), New CVRM3 by 15% (19% at CER) and, driven by the strength of Fasenra, Respiratory sales increased by 9% (14% at CER). Emerging Markets sales increased by 14% (22% at CER);